• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

胚系 DNA 修复基因突变与阿比特龙或恩杂鲁胺在转移性去势抵抗性前列腺癌患者中的疗效。

Germline DNA-repair Gene Mutations and Efficacy of Abiraterone or Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer.

机构信息

Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.

Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.

出版信息

Eur Urol Focus. 2019 Sep;5(5):745-747. doi: 10.1016/j.euf.2019.02.011. Epub 2019 Feb 21.

DOI:10.1016/j.euf.2019.02.011
PMID:30797739
Abstract
  1. mCRPC patients with gDDRm exhibit a good response to first abiraterone/enzalutamide treatments, despite this was not statistically significant. 2. The different detections of gDDRm and treatments (abiraterone or enzalutamide), indeed, are influential factors.
摘要
  1. 尽管没有统计学意义，但存在 gDDRm 的 mCRPC 患者对首次阿比特龙/恩扎卢胺治疗有良好的反应。2. 确实，gDDRm 和治疗（阿比特龙或恩扎卢胺）的不同检测是影响因素。

相似文献

1
Germline DNA-repair Gene Mutations and Efficacy of Abiraterone or Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer.胚系 DNA 修复基因突变与阿比特龙或恩杂鲁胺在转移性去势抵抗性前列腺癌患者中的疗效。
Eur Urol Focus. 2019 Sep;5(5):745-747. doi: 10.1016/j.euf.2019.02.011. Epub 2019 Feb 21.
2
Germline DNA-repair Gene Mutations and Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Receiving First-line Abiraterone and Enzalutamide.种系 DNA 修复基因突变与一线接受阿比特龙和恩杂鲁胺治疗的转移性去势抵抗性前列腺癌男性的结局
Eur Urol. 2018 Aug;74(2):218-225. doi: 10.1016/j.eururo.2018.01.035. Epub 2018 Feb 10.
3
Wnt-pathway Activating Mutations Are Associated with Resistance to First-line Abiraterone and Enzalutamide in Castration-resistant Prostate Cancer.Wnt信号通路激活突变与去势抵抗性前列腺癌对一线阿比特龙和恩杂鲁胺的耐药性相关。
Eur Urol. 2020 Jan;77(1):14-21. doi: 10.1016/j.eururo.2019.05.032. Epub 2019 Jun 5.
4
[Enzalutamide and Abiraterone in the Treatment of Metastatic Castration-resistant Prostate Cancer after Chemotherapy].恩杂鲁胺与阿比特龙治疗化疗后转移性去势抵抗性前列腺癌
Klin Onkol. 2016;29(2):127-32. doi: 10.14735/amko2016127.
5
Evaluation of PSMA expression changes on PET/CT before and after initiation of novel antiandrogen drugs (enzalutamide or abiraterone) in metastatic castration-resistant prostate cancer patients.评估新型抗雄激素药物（恩扎卢胺或阿比特龙）治疗转移性去势抵抗性前列腺癌患者前后 PSMA 表达变化的 PET/CT。
Ann Nucl Med. 2019 Dec;33(12):945-954. doi: 10.1007/s12149-019-01404-2. Epub 2019 Oct 5.
6
Comparing the clinical efficacy and safety of abiraterone and enzalutamide in metastatic castration-resistant prostate cancer: A systematic review and meta-analysis.比较阿比特龙和恩杂鲁胺在转移性去势抵抗性前列腺癌中的临床疗效和安全性：系统评价和荟萃分析。
J Oncol Pharm Pract. 2021 Apr;27(3):614-622. doi: 10.1177/1078155220929414. Epub 2020 Jun 12.
7
What do we know about treatment sequencing of abiraterone, enzalutamide, and chemotherapy in metastatic castration-resistant prostate cancer?我们对阿比特龙、恩杂鲁胺和化疗在转移性去势抵抗性前列腺癌中的治疗顺序了解多少？
World J Urol. 2016 May;34(5):617-24. doi: 10.1007/s00345-015-1687-0. Epub 2015 Sep 15.
8
Third-line Enzalutamide Following Docetaxel and Abiraterone in Metastatic Castrate-resistant Prostate Cancer.多西他赛和阿比特龙治疗后使用恩杂鲁胺作为转移性去势抵抗性前列腺癌的三线治疗
Anticancer Res. 2016 Apr;36(4):1799-803.
9
Prognostic value of 18F-choline PET/CT metabolic parameters in patients with metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide.18F-胆碱 PET/CT 代谢参数对接受阿比特龙或恩杂鲁胺治疗的转移性去势抵抗性前列腺癌患者的预后价值。
Eur J Nucl Med Mol Imaging. 2018 Mar;45(3):348-354. doi: 10.1007/s00259-017-3866-2. Epub 2017 Nov 6.
10
Health-related Quality of Life for Abiraterone Plus Prednisone Versus Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer: Results from a Phase II Randomized Trial.阿比特龙联合泼尼松与恩杂鲁胺治疗转移性去势抵抗性前列腺癌患者的健康相关生活质量：一项 II 期随机试验结果。
Eur Urol. 2019 Jun;75(6):940-947. doi: 10.1016/j.eururo.2018.12.015. Epub 2018 Dec 24.

引用本文的文献

1
Germline Mutations in Patients With Early-Onset Prostate Cancer.早发性前列腺癌患者的种系突变
Front Oncol. 2022 Jun 6;12:826778. doi: 10.3389/fonc.2022.826778. eCollection 2022.